Global Breast Cancer Market Size, Industry Analysis, Innovation, Overview, Growth Rate, Share and Forecasts

Latest industry research report on: Global Breast Cancer Market | Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts

The breast cancer pipeline is the largest in the pharmaceutical industry, with 1,050 products in active development across all stages. The range of mechanisms of action employed by these compounds is also highly diverse, especially in comparison to the existing market landscape. The degree and proportion of breakthrough innovations in this pipeline is exceptional & GBI Research analysis identified 333 first-in-class programs in the breast cancer pipeline, acting on 251 first-in-class molecular targets. This accounts for some 39% of all products with a disclosed molecular target, and is reflective of the high degree of innovation in this indication. This has far-reaching strategic implications for all market participants, as despite the high attrition rate in breast cancer, it is highly likely many of the first-in-class products will reach the market over the coming decade and, will have the opportunity to transform the clinical and commercial landscape.

Potential driving factors behind this market include a very large and growing patient pool, a well-established disease market with a number of strong unmet needs, and the strong understanding of the disease pathophysiology that has developed over the last decade, facilitating the development of novel compounds that may fill the unmet needs.

Some 289 first-in-class products that are currently in development have not yet been involved in licensing or co-development deals, meaning there are numerous opportunities for in-licensing or co-development in this indication, which already has a strong track record of breakthrough innovation yielding highly commercially and clinically successful therapies.

Download Sample copy of this Report at : http://www.marketresearchreports.biz/sample/sample/668359

Scope

• The report analyzes innovation in breast cancer, in the context of the overall pipeline and current market landscape. In addition, it analyzes the deals landscape surrounding first-in-class products in breast cancer, and pinpoints opportunities for in-licensing.
• A brief introduction to breast cancer, including symptoms, pathophysiology, and an overview of pharmacotherapy and treatment algorithms.
• The changing molecular target landscape between the market and the pipeline, and particular focal points of innovation in the pipeline.
• Comprehensive review of the pipeline for first-in-class therapies, analyzed on the basis of stage of development, molecule type and molecular target.
• Identification and assessment of first-in-class molecular targets, with a particular focus on early-stage programs for which clinical utility has yet to be evaluated, as well as literature reviews on novel molecular targets.
• Assessment of the licensing and co-development deal landscape for breast cancer therapies, and benchmarking of deals involving first-in-class versus non-first-in-class-products.

Reasons to buy

• Understand the current clinical and commercial landscape, including a comprehensive study of disease pathogenesis, diagnosis, prognosis and the available treatment options available at each stage of diagnosis.
• Visualize the composition of the breast cancer market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of the gaps in the current market.
• Analyze the breast cancer pipeline, stratified by stage of development, molecule type and molecular target.
• Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been further reviewed in greater detail.
• Identify commercial opportunities in the breast cancer deals landscape by analyzing trends in licensing and co-development deals, and producing a list of breast cancer therapies that are not yet involved in deals and may be potential investment opportunities.

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074

Website: http://www.marketresearchreports.biz/

E: sales@marketresearchreports.biz

Asia-Pacific Asthma Therapeutics Market Will Hit At $5.6 billion till year 2021

Latest industry research report on: Asia-Pacific Asthma Therapeutics Market : Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts

Asthma is a common chronic inflammatory disease of the airways, characterized by recurrent attacks of breathlessness and wheezing, which vary in frequency and severity from patient to patient. The exact causes of asthma are currently unknown, and may be the result of a combination of factors, although two major factors thought to be involved are environmental exposure and host factors, particularly genes.

Asthma treatment can be classed as either a long-term control medication, aimed at controlling persistent asthma, or a quick-relief medication, for the relief of exacerbations and acute symptoms. Long-term control medication includes Inhaled Corticosteroids (ICS), immunomodulators, leukotriene modifiers, cromolyn sodium, nedocromil and methylxanthines. In addition, Long-Acting Beta-Adrenoceptor Agonists (LABAs) can be used in combination with ICSs – but not as monotherapies – for moderate or severe persistent asthma. Currently, only one biologic – Xolair (omalizumab) – is approved as an add-on therapy for the treatment of allergic asthma in the Asia-Pacific region. Nevertheless, significant unmet need remains for the treatment of severe eosinophilic asthma.

Download Sample copy of this Report at : http://www.marketresearchreports.biz/sample/sample/686317

Scope

The current asthma market in the Asia-Pacific region contains novel products, including Xolair, a recombinant humanized monoclonal anti-IgE antibody; Seretide/Adoair, an ICS-LABA combination therapy; Relvar/Breo, an ICS-LABA combination therapy, and Spiriva, a LAMA.

• What are the competitive advantages of the existing novel drugs?

With over 274 active pipeline molecules, most of the late-stage investigational drug candidates are being evaluated, with improved dosing regimens and administration routes in comparison to currently marketed products.

• Which classes of novel drugs are most prominent within the pipeline?
• Is there strong potential for the pipeline to address unmet needs within the asthma market – specifically for severe eosinophilic asthma?

Analysis of clinical trials since 2006 has identified that the failure rates of asthma molecules were highest in Phase III (46%), with the overall attrition rate for asthma in development being 78%.

• How do failure rates vary by product stage of development, molecule type, and mechanism of action?
• How do other factors, such as average trial duration and trial size influence the costs and risks associated with product development?
• Over the 2014–2021 forecast period, the asthma therapeutics market in the Asia-

Pacific region is expected to increase in value at a Compound Annual Growth Rate (CAGR) of 7.2%, from $3.5 billion to over $5.6 billion.

• Which markets make the most significant contribution to the current market size?
• What are the epidemiology trends in these markets?
• Will new market entrants lead to substantial changes in annual therapy costs?
• How will different treatment usage patterns impact growth in the five assessed Asia-Pacific markets?

Rising asthma prevalence and uptake of newer biologics will lead to significant market growth over the forecast period, in spite of affordability concerns.

• Will affordability threaten the commercial success of existing drugs as well as newer biologics?
• Which of the assessed countries have affordability concerns?

Reasons to buy

This report will enable you to -

• Understand the clinical context of asthma by considering symptoms, etiology, pathophysiology, epidemiology, diagnosis, and treatment options.
• Identify the therapeutic strategies, products, and companies that dominate the current marketed products landscape and recognize gaps and areas of unmet need.
• Identify key pipeline trends in molecule type, administration route, mechanism of action, and novelty.
• Consider market opportunities and potential risks by examining trends in asthma clinical trial size, duration, and failure rate by stage of development, molecule type, and mechanism of action.
• Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential in asthma by examining clinical trial data and multi-scenario product forecast projections.
• Compare treatment usage patterns, annual therapy costs, and market growth projections for China, India, Australia, South Korea and Japan.
• Discover trends in licensing and co-development deals concerning asthma products and identify the major strategic consolidations that have shaped the commercial landscape.

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074

Website: http://www.marketresearchreports.biz/

E: sales@marketresearchreports.biz

Asia-Pacific Alzheimers Therapeutics Market Will Reach At $5.1 billion in 2021

Latest industry research report on: Asia-Pacific Alzheimers Therapeutics Market | Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts

Alzheimers Disease (AD) is an irreversible, progressive neurodegenerative disease, characterized by cognitive impairment, memory loss and functional decline. Symptoms typically begin to first occur in patients in their mid-sixties, appearing in varying stages. The pathological features of AD comprise histopathological changes within the brain. Mild Cognitive Impairment (MCI) is a heterogeneous condition between normal cognition and dementia, whereby cognitive changes in mental abilities, such as memory or thinking, are affected. Almost all cases of AD begin with MCI, but it should be noted that not all patients with MCI go on to develop AD.

Although there is a high degree of failure and uncertainty within the R&D of AD drugs, the number of drugs in the pipeline is considerable, at 559. The majority of the pipeline products are novel, and there are only seven repositioned drugs and five generic drugs. This shows progression in terms of the different molecules being developed as therapeutic agents within the AD pipeline.

Download Sample copy of this Report at : http://www.marketresearchreports.biz/sample/sample/686320

Scope

The AD market has a lack of therapeutic options.

• Which classes of drug dominate the market?
• What newly approved therapies have entered the market?
• How do the leading marketed therapies compare clinically?
• How will the new therapies be positioned in the treatment of AD?
• How have selected late-stage pipeline therapies performed in clinical trials?

The pipeline contains a range of molecule types and molecular targets, including those that are well established in AD, and novel, first-in-class therapies.

• Which molecular targets appear most frequently in the pipeline?

AD clinical trials have an overall attrition rate of 94%.

• What are the failure rates for individual Phases of clinical development?
• How do AD clinical trial characteristics, including failure rate, duration, and size compare against respiratory and industry averages?

The AD market is forecast to rise from a value of $3 billion in 2014 to $5.1 billion in 2021, at a CAGR of 7.9% across the four Asia-Pacific markets assessed.

• How much of a role will disease prevalence and new product approvals play in market growth?
• Will generic competition have a significant impact on the market over the forecast period?

There have been 170 licensing deals and 104 co-development deals pertaining to AD products since 2006.

• Which territories show the most deal activity?
• What were the trends in deal completion by product stage of development?
• What were the conditions of the key licensing or co-development deals to take place in AD?

Reasons to buy

This report will allow you to -

• Understand the current clinical and commercial landscape through a comprehensive study of disease pathogenesis, diagnosis, prognosis, and the current treatment algorithm used in AD.
• Assess the safety and efficacy of current treatment options, with extensive product profiles on prominent marketed therapies, and a heatmap directly comparing safety and efficacy data.
• Analyze the AD pipeline and stratify by stage of development, molecule type, and molecular target. The most promising late-stage therapies are profiled and assessed in terms of clinical performance and competitiveness, alongside a single-product forecast.
• Predict growth in market size in four Asia-Pacific markets, with in-depth market forecasting from 2014 to 2021. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and patent expirations will influence market value.
• Identify commercial opportunities in the AD deals landscape by analyzing trends in licensing and co-development deals, and by profiling the most significant deals that have occurred in this indication in recent years.

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074

Website: http://www.marketresearchreports.biz/

E: sales@marketresearchreports.biz

Global Acute Myeloid Leukemia Market Size, Industry Analysis, Technology advancement, Overview, Growth Rate, Share and Forecasts

Latest industry research report on: Global Acute Myeloid Leukemia Market : Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts

Acute Myeloid Leukemia (AML) is a rare but serious disease, and the most common leukemia suffered by adults. The first-line treatment in eligible patients is almost always intensive chemotherapy. Despite strong initial remission rates, relapse is common, and AML has the lowest five-year survival rate of all leukemias, at 25%. Efforts have been made to introduce novel therapies to the AML market, but its treatment has changed little in the last 40 years. However, a number of products are currently in late-stage development for the treatment of AML, both before and after the induction of remission and relapse.

This tabular heat map framework, designed to provide an easily digestible summary of these clinical characteristics, provides detailed information on all late-stage clinical trial results for products in the AML market and Phase III pipeline. These are split along therapy lines, and are therefore reflective of the treatment algorithm used in the clinic.

All safety and efficacy endpoints reported in these trials are displayed, for both the drug and placebo groups. In addition, key study characteristics such as the size, composition and patient segment of the study population are provided. These results are presented in a visually accessible, color-coded manner in order to maximize ease of use.

Download Sample copy of this Report at : http://www.marketresearchreports.biz/sample/sample/915794

The accompanying text provides a detailed analysis of the clinical benchmarks set by the current market landscape, and the anticipated changes to these benchmarks, and to the treatment algorithm, as a result of the late-stage pipeline.

Scope

• What are the clinical characteristics of currently approved therapies for AML, in terms of specific safety and efficacy parameters?
• What are the key unmet needs in this indication, and which clinical safety and efficacy parameters are the most closely linked to them?
• A number of pipeline therapies are in the late-stage pipeline for the post-relapse setting, but do they have sufficient differentiating characteristics to make a strong impact on the market and clinic?
• Which line of therapy in AML stands to benefit most from the current late-stage pipeline?
• Will current pipeline targeted therapies be able to successfully enter the market for AML, or will chemotherapy remain the treatment modality of choice in this indication for the foreseeable future?

Reasons to buy

• Understand the current clinical landscape by considering the treatment options available for each patient segment.
• Visually compare the currently approved treatments available at each line of therapy, based on the most important efficacy and safety parameters tested in clinical trials.
• Assess the current late-stage pipeline, in terms of the likely positioning of each product and the implications for the clinical landscape at each line of therapy.
• Understand the relative strengths and weaknesses of the studies used to gather these data.
• Build up a nuanced understanding of the clinical benchmarks set by these products, and consider how the current late-stage pipeline will affect these benchmarks.
• Assess your own pipeline programs in light of these benchmarks, in order to optimally position them and maximize uptake by clinicians.

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074

Website: http://www.marketresearchreports.biz/

E: sales@marketresearchreports.biz

Global Diabetes Mellitus Market Size, Industry Analysis, Emerging Evolution, Overview, Growth Rate, Share and Forecasts

Latest industry research report on: Global Diabetes Mellitus Market | Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts

Type 2 diabetes mellitus (T2DM) is a chronic, progressive and serious metabolic disorder characterized by hyperglycemia (high blood glucose levels) and associated with numerous complications and co-morbidities, including cardiovascular disease, nephropathy (kidney damage), neuropathy (nerve damage) and retinopathy (retinal damage).

Global prevalence of the disease has risen rapidly in the past several decades, primarily as a result of rising obesity, a major risk factor for T2DM. This has resulted in a large, diverse and rapidly growing market landscape, comprising numerous different drug classes.

In particular, the emergence over the past decade of glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase 4 (DPP-4) inhibitors and sodium-glucose linked transporter-2 (SGLT-2) inhibitors has intensified competition. These new drug classes have been highly commercially successful, leading to considerable market growth. With a highly active late-stage pipeline, this trend is expected to continue over the coming years.

Sample copy of this Report @http://www.marketresearchreports.biz/sample/sample/915801

Differences between these products must be understood fully by companies seeking to position a novel drug in this market. This tabular heat map framework, designed to provide an easily digestible summary of these clinical characteristics, provides detailed readouts of all major late-stage clinical trial results for products in the T2DM market and late-stage pipeline. These are split along lines of therapy, and so are reflective of the treatment algorithm used in the clinic.

All safety and efficacy endpoints reported in these trials are displayed, for both the drug and control groups. In addition, key study characteristics such as the size, composition and patient segment of the study population are provided. These results are presented in a visually accessible, color-coded manner in order to maximize ease of use.

The accompanying text provides a detailed analysis of the clinical benchmarks set by the current market landscape, and the anticipated changes to these benchmarks, and to the treatment algorithm, as a result of the late-stage pipeline.

Scope

• What are the clinical characteristics of currently approved therapies for T2DM, in terms of specific safety and efficacy parameters?
• Will metformin continue to be the preferred first-line therapy? 
• How will established drug classes such as the GLP-1 receptor agonists be impacted by upcoming pipeline competitors? 
• Will biosimilar erosion significantly impact the insulin market?
• What technologies are late-stage pipeline therapies employing to improve patient convenience and ease of use?

Reasons to buy

• Understand the current clinical landscape by considering the treatment options available for each patient segment.
• Visually compare the currently approved treatments available at each line of therapy, based on the most important efficacy and safety parameters tested in clinical trials.
• Assess the current late-stage pipeline, in terms of the likely positioning of each product and the implications for the clinical landscape at each line of therapy. 
• Build up a nuanced understanding of the clinical benchmarks set by these products, and consider how the current late-stage pipeline will affect these benchmarks. 
• Assess your own pipeline programs in light of these benchmarks, in order to optimally position them and maximize uptake by clinicians.

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074

Website: http://www.marketresearchreports.biz/

E: sales@marketresearchreports.biz

Diabetes Mellitus Therapeutics in South-East Asia Market Size, Industry Analysis, Technology advancement, Overview, Share and Forecasts

Latest industry research report on: Diabetes Mellitus Therapeutics in South-East Asia Market | Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts

Diabetes mellitus is a group of metabolic diseases characterized by chronic hyperglycemia - high blood glucose levels - that results from defects in insulin secretion, insulin action, or a combination of these. This chronic hyperglycemia is associated with long-term damage, dysfunction and failure of multiple organs, including the eyes, kidneys, nerves, heart and blood vessels. The vast majority of diabetes mellitus patients can be classified as having either Type 1 Diabetes Mellitus (T1DM) or Type 2 Diabetes Mellitus (T2DM). Approximately 90-95% of all diabetics have T2DM.

T2DM treatment has been revolutionized in the past decade, especially with the increased use of new therapies. The marketed products landscape comprises a wide range of treatment options, including biguanide (metformin), sulfonylureas, thiazolidinediones, GLP-1 receptor agonists, DPP-4 inhibitors, SGLT-2 inhibitors, and insulin therapies. Nevertheless, significant unmet need remains for products that can offer better glycemic control, as well as the prevention and cure of diabetic complications, such as diabetic nephropathy, retinopathy, and cardiovascular disease.

Sample copy of this Report @http://www.marketresearchreports.biz/sample/sample/811828

Scope

The current South-East Asia T2DM market contains novel products, including Jardiance, a SGLT-2 inhibitor; Victoza, a GLP-1 receptor agonist; and Januvia, a DPP-4 inhibitor.

• What are the competitive advantages of the existing novel drugs?

With over 500 active pipeline molecules, most of the late-stage investigational drug candidates are being evaluated, featuring improved dosing regimens and administration routes in comparison to currently marketed products and combination therapies.

• Which classes of novel drugs are most prominent within the pipeline?
• Is there strong potential for the pipeline to address unmet needs within the T2DM market?

Analysis of clinical trials since 2006 identified that the failure rates of T2DM molecules were highest in Phase III, at 49%, with the overall attrition rate for T2DM standing at 75%.

• How do failure rates vary by product stage of development, molecule type, and mechanism of action?
• How do other factors, such as average trial duration and trial size, influence the costs and risks associated with product development?

Over the 2015-2022 forecast period, the South-East Asia T2DM therapeutics market is expected to increase in value at a CAGR of 7.1%, from $1.7 billion to over $2.7 billion.

• Which markets make the most significant contribution to the current market size?
• What are the epidemiology trends in these markets?
• Will new market entrants lead to substantial changes in annual therapy costs?
• How will different treatment usage patterns impact growth in the eight assessed South-East Asia markets?

Rising T2DM prevalence and the uptake of newer therapies will lead to significant market growth over the forecast period, despite generic sales erosion resulting from patent expirations.

• Will patent expirations or emerging pipeline molecules threaten the commercial success of existing drugs?

Reasons to buy

This report will enable you to - 

• Understand the clinical context of T2DM by considering symptoms, etiology, pathophysiology, epidemiology, diagnosis, and treatment options.
• Identify the therapeutic strategies, products, and companies that dominate the current marketed products landscape and recognize gaps and areas of unmet need.
• Identify key pipeline trends in molecule type, administration route, mechanism of action, and novelty.
• Consider market opportunities and potential risks by examining trends in T2DM clinical trial size, duration, and failure rate by stage of development, molecule type, and mechanism of action.
• Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential in T2DM by examining clinical trial data and multi-scenario product forecast projections.
• Compare treatment usage patterns, annual therapy costs, and market growth projections for South Korea, Singapore, Taiwan, Malaysia, the Philippines, Thailand, Vietnam, and Indonesia.
• Discover trends in licensing and co-development deals concerning T2DM products and identify the major strategic consolidations that have shaped the commercial landscape.

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074

Website: http://www.marketresearchreports.biz/

E: sales@marketresearchreports.biz

COPD Therapeutics Asia-Pacific Market Will Reach At USD7.3 bn till year 2022

Latest industry research report on: Asia-Pacific COPD Therapeutics Market | Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts

Chronic obstructive pulmonary disease (COPD) is a term that refers to a large group of lung diseases characterized by obstruction of air flow that interferes with normal breathing. COPD occurs most often in older people, but can also affect people in their middle ages. It is a major cause of chronic morbidity and mortality globally. Many people suffer from this disease for years, and die from it or its complications, and it constitutes a substantial economic and social burden.

Globally, the COPD burden is projected to increase in the coming decades because of continued exposure to COPD risk factors, and the increasing number of smokers. Increased smoking will result in a greater number of people living with the condition, thereby acting as a driver for revenue growth. The share of mortality attributed to COPD is expected to increase in the coming decades, when compared with other chronic diseases such as heart disease and stroke.

The marketed products landscape comprises a wide range of treatment options, including bronchodilator combinations, bronchodilator and ICS combinations, bronchodilator monotherapies and PDE-4 inhibitors. However, the market is undergoing a gradual transition, away from bronchodilator and ICS therapies and towards targeted and triple combination drug treatments. The market is set to be driven by recently launched products, and the approval of novel drugs that will supplement current market leaders and offer greater therapeutic options.

Download Sample copy of this Report at : http://www.marketresearchreports.biz/sample/sample/938607

Scope

• The COPD Asia-Pacific market will be valued at $7.3 billion in 2022, growing from $3.7 billion in 2015 at a CAGR of 10.2%.

• Bronchodilators and ICS dominate the COPD market, but unmet needs exist in terms of safety and efficacy. Will the drugs under development fulfill the unmet needs of the COPD market?
• Do branded therapies show continuous growth, and are they facing any competition from generics?
• How will branded therapies be affected by upcoming pipeline therapies?

The pipeline contains a range of molecule types and molecular targets, including those that are well established in COPD, and novel, first-in-class therapies.

- Which molecular targets appear most frequently in the pipeline?

• Will the pipeline address unmet needs related to limited targeted therapies for COPD patients?
• What first-in-class triple combinations are due to enter the COPD market within the forecast period, and how will they compete with the currently marketed products?

Market forecasts indicate that Japan will contribute the most to the Asia-Pacific market value, due to the emergence of novel therapies.

• How will the annual cost of therapy and market size vary between the five Asia-Pacific markets?
• Various drivers and barriers will influence the market over the forecast period.
• What barriers limit the uptake of premium-priced therapeutics in the assessed countries?
• What factors are most likely to drive the market in these countries?

Reasons to buy

This report will allow you to -

• Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
• Visualize the composition of the COPD market in terms of dominant therapies, with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the current market.
• Analyze the COPD pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
• Understand the potential of late-stage therapies, with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
• Predict COPD market growth in the five Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as analysis of the contributions of promising late-stage molecules to market growth.
• Identify commercial opportunities in the COPD deals landscape by analyzing trends in licensing and co-development deals.

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074

Website: http://www.marketresearchreports.biz/

E: sales@marketresearchreports.biz

Global Colorectal Cancer Market Size, Industry Analysis, Innovation, Overview, Growth Rate, Share and Forecasts

Latest industry research report on: Global Colorectal Cancer Market : Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts

Colorectal cancer (CRC), otherwise known as bowel cancer, is a malignancy originating in the colon (the large intestine) or rectum, both of which are located towards the end of the human gastrointestinal tract. It begins as a benign tumor, which is almost always in the form of a small polyp within the colon or rectum. It rarely occurs in the absence of polyps, although can arise as a result of an inflammatory bowel disease such as Crohn’s disease or ulcerative colitis. CRC was the third most prolific oncological indication with regard to the number of new cases in the US in 2016.

The disease can be divided into two categories based on how advanced it is upon diagnosis. These are early-stage (adjuvant) CRC, which can be treated with surgery, and metastatic (advanced) CRC, which cannot. Therapeutic options differ between the two treatment settings, with therapies for adjuvant CRC aiming to prevent disease re-occurrence and those for advanced conditions aiming to slow disease progression while maintaining the patient’s quality of life.

Targeted therapies have already begun to extend the lifespan of metastatic CRC patients compared with chemotherapy-only regimens. However, there remains an unmet need to improve the efficacy of treatment options and extend survival for these patients. Additionally, an unmet need exists for patients with KRAS mutation-positive CRC, for whom certain currently marketed therapies are not recommended.

This tabular heatmap framework, designed to provide an easily digestible summary of these clinical characteristics, provides detailed information on all late-stage clinical trial results for products in the CRC market, with additional focus on the late-stage pipeline. These are split along therapy lines, and are therefore reflective of the treatment algorithm.

Download Sample copy of this Report at : http://www.marketresearchreports.biz/sample/sample/984797

All safety and efficacy endpoints reported in these trials are displayed, for both the drug and placebo groups. In addition, key study characteristics such as the size, composition and patient segment of the study population are provided. These results are presented in a visually accessible, color-coded manner in order to maximize ease of use.

The accompanying text provides a detailed analysis of the clinical benchmarks set by the current market landscape, and the anticipated changes to these benchmarks, and to the treatment algorithm, as a result of the late-stage pipeline.

Scope

• How is the colorectal cancer market landscape expected to change with regard to therapeutic type, due to promising pipeline therapies?
• What are the clinical characteristics of currently approved therapies for colorectal cancer, in terms of specific safety and efficacy parameters?
• How are clinical safety and efficacy parameters linked to the key unmet needs in this indication?
• How will current late-stage immunotherapeutics affect the colorectal cancer market, and will they be able to satisfy current unmet need with regard to effective therapy options?
• Are future product approvals likely to affect the treatment algorithm significantly?

Reasons to buy

• Understand the current clinical landscape by considering the treatment options available for earlyand late-stage disease.
• Visually compare the currently approved treatments available at each line of therapy, based on the most important efficacy and safety parameters tested in clinical trials.
• Assess the current late-stage pipeline, in terms of the likely positioning of each product and the implications for the clinical landscape at each line of therapy.
• Understand the relative strengths and weaknesses of the studies used to gather these data.
• Build up a nuanced understanding of the clinical benchmarks set by these products, and consider how the current late-stage pipeline will affect these benchmarks.
• Assess your own pipeline programs in light of these benchmarks in order to optimally position them and maximize uptake by clinicians.

Table of Contents

1 Table of Contents

1 Table of Contents 2

2 Introduction 3

2.1 Report Guidance 6

3 Marketed Products 7

3.1 Early-Stage Adjuvant Therapy 7

3.2 Advanced (Unresectable or Metastatic) Therapy 8

3.2.1 Chemotherapy 9

3.2.2 Targeted Therapies 10

4 Pipeline Products 13

4.1 Changes to Early-Stage Adjuvant Therapies, 2017–2022 13

4.2 Changes to Advanced (Unresectable or Metastatic) Therapies, 2017–2022 13

4.2.1 Changes to Chemotherapies, 2017–2022 13

4.2.2 Changes to Targeted Therapies, 2017–2022 14

5 Appendix 17

5.1 Abbreviations 17

5.2 References 18

5.3 Research Methodology 21

5.4 Contact Us 21

5.5 Disclaimer 21

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074

Website: http://www.marketresearchreports.biz/

E: sales@marketresearchreports.biz